Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Retained Earnings (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Retained Earnings for 8 consecutive years, with -$879.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 39.86% year-over-year to -$879.6 million, compared with a TTM value of -$879.6 million through Sep 2025, down 39.86%, and an annual FY2024 reading of -$680.8 million, down 52107.9% over the prior year.
  • Retained Earnings was -$879.6 million for Q3 2025 at Bicycle Therapeutics, down from -$3.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $2.9 million in Q3 2023 and bottomed at -$879.6 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$199.8 million, with a median of -$3.4 million recorded in 2025.
  • The sharpest move saw Retained Earnings skyrocketed 111.42% in 2022, then plummeted 95214.27% in 2025.
  • Year by year, Retained Earnings stood at -$3.4 million in 2021, then surged by 111.42% to $387000.0 in 2022, then crashed by 436.95% to -$1.3 million in 2023, then tumbled by 52107.9% to -$680.8 million in 2024, then dropped by 29.2% to -$879.6 million in 2025.
  • Business Quant data shows Retained Earnings for BCYC at -$879.6 million in Q3 2025, -$3.4 million in Q2 2025, and -$741.5 million in Q1 2025.